Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00265109 · ClinicalTrials.gov registry record · Phase 4
Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder
A Phase 4 study of Body Dysmorphic Disorder, sponsored by Butler Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT00265109: Completed Phase 4 study of Body Dysmorphic Disorder, sponsored by Butler Hospital.
NCT00265109 is a Phase 4 study of Body Dysmorphic Disorder that has completed, run by Butler Hospital. The registered enrollment target is 17 participants, below the 163-participant average among 3 other Body Dysmorphic Disorder trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00265109, a Phase 4 study of Body Dysmorphic Disorder, has completed, sponsored by Butler Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the usefulness of a medication (Levetiracetam) for people with body dysmorphic disorder.
Primary Outcome
The BDD-YBOCS, a reliable and valid 12-item semi-structured clinician-administered scale assessed BDD severity during the past week. 38 items are rated from 0 (no symptoms) to 4 (extreme symptoms); range=0-48. This scale assesses preoccupation with the perceived appearance defects, associated compulsive behaviors, insight, and avoidance. A ≥30% decrease in total score indicated response.
Conditions Studied
Interventions
- DRUG Levetiracetam
Study Locations (1)
Rhode Island
- Rhode Island Hospital Body Dysmorphic Disorder Program - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2004-12 |
| Est. Completion | 2008-01 |
| Phase | Phase 4 |
What the finished NCT00265109 record still lists
NCT00265109 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 163-participant average among 3 other Body Dysmorphic Disorder trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Body Dysmorphic Disorder appearing as the primary indexed condition, and to 1 intervention - of which Levetiracetam is the first listed.
NCT00265109 reports a single indexed study location in Rhode Island.
Frequently Asked Questions
What is clinical trial NCT00265109 about?
NCT00265109 is a clinical study titled "Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder". The purpose of this study is to assess the usefulness of a medication (Levetiracetam) for people with body dysmorphic disorder.
What is the current status of trial NCT00265109?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 17 participants. The study started on 2004-12. Estimated completion is 2008-01.
What conditions does trial NCT00265109 study?
This clinical trial studies the following conditions: Body Dysmorphic Disorder.
What interventions are being tested in trial NCT00265109?
The interventions under investigation include: Levetiracetam (DRUG).
Who is sponsoring clinical trial NCT00265109?
This trial is sponsored by Butler Hospital, which has 103 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00265109 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Body Dysmorphic Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Individual Factors of CBT Underlying Success
RECRUITING · NA
-
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals
ACTIVE NOT RECRUITING · NA
-
Waitlist-Control Trial of Smartphone Cognitive Behavioral Therapy (CBT) for Body Dysmorphic Disorder (BDD)
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia